Loading...
Loading...
ALT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 13.3M |
| Gross Profit | -13.2M |
| Operating Expense | 18.0M |
| Operating I/L | -18.0M |
| Other Income/Expense | 0.1M |
| Interest Income | 1.8M |
| Pretax | -16.1M |
| Income Tax Expense | 0.6M |
| Net Income/Loss | -16.1M |
Altimmune, Inc. is a clinical stage biopharmaceutical company specializing in developing treatments for obesity and liver diseases. Their lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist in Phase 1b trial for obesity and non-alcoholic steatohepatitis. Additionally, they are developing HepTcell, an immunotherapeutic product candidate in Phase 2 clinical trial for chronic hepatitis B virus infection. Altimmune, Inc. generates revenue through the development and potential commercialization of these innovative pharmaceutical products aimed at addressing significant unmet medical needs in the obesity and liver disease markets.
